EUVIMEDEUVIMED entdecken
Klinische Studie

A pilot study of [18F]F-fluciclovine positron emission tomography/computed tomography for staging muscle invasive bladder cancer preceding radical cystectomy

Thomas S C Ng iD, Mofei Liu, Matthew Robertson, Arda Könik, Su Chun Cheng, Martin K Bakht, Kristen Harrington, Andrew Wolanski, Lauren Gilbert, Mark Preston, Matthew Mossanen, Himisha Beltran und 3 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2025-09 · 52 (11) · 4092-4101

DOI: 10.1007/s00259-025-07287-y ↗

Kurz gefasst

Klinische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 21.04.2025. Verfasst von Thomas S C Ng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Imaging, Dana-Farber Cancer Institute, Boston, MA, USA. scng@mgb.org. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Positron Emission Tomography Computed Tomography, Cyclobutanes, Cystectomy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: U.S. Department of Defense, NIH HHS, Lee Family Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: To assess the ability of [18F]F-fluciclovine-PET/CT to stage muscle invasive bladder cancer (MIBC) before radical cystectomy. METHODS: This single-site prospective pilot study enrolled patients with MIBC and T2-T4, N0 disease on CT/MRI slated to undergo radical cystectomy (RC). Dynamic and static [18F]F-fluciclovine-PET/CT images were acquired. Clinical readers assessed for confirmation of the primary bladder lesion on imaging and the presence of pelvic nodal metastases. Findings were compared to pathology at RC. Kinetic parameters from dynamic PET/CT were compared across bladder lesions of different clinical stages. RESULTS: The study enrolled sixteen patients (median age: 73 years, range: 57-88 years, 11 males, 5 females), twelve receiving neoadjuvant chemotherapy before RC. There was high specificity amongst all three readers for detecting lymph node metastases (overall specificity: 0.91, 95%CI: 0.81-1.00) with good overall agreement rate with pathology (0.67, 95%CI: 0.44-0.83). The overall PPV for all readers for identifying node-positive disease was 0.4 (95%CI: 0-1.00), and the overall sensitivity was 0.13 (95%CI: 0-0.44). The overall PPV for detecting the primary tumor was 0.69 (95%CI: 0.47-0.88), and the sensitivity was 0.89 (95%CI: 0.78-1.00), with NPV and specificity being 0.70 (95%CI: 0.33, 1.00) and 0.39 (95%CI: 0.33, 0.50), respectively. Compartmental analysis of the primary bladder tumor revealed that k1 and vb parameters significantly differentiated between low (pT0-pT1) and high (pT2-pT4) risk disease (p < 0.05). Immunohistochemical assessment showed no significant correlation of tumor [18F]F-fluciclovine uptake nor kinetic parameter with amino acid transporter expression. CONCLUSIONS: [18F]F-fluciclovine demonstrates good specificity and agreement rate for MIBC staging, with sensitivity like CT/MRI. Kinetic parameters such as k1 was able to delineate higher-stage ( ≥ = pT2) primary lesions. Heterogeneous amino acid transporter expression can be seen across lesions. Further studies are warranted to understand [18F]F-fluciclovine PET/CT use in the context of other imaging modalities in this disease. CLINICAL TRIAL REGISTRATION: NCT04018053 Registered 2/26/2020.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsPositron Emission Tomography Computed TomographyCyclobutanesCystectomyCarboxylic AcidsHumansAgedMaleFemaleMiddle AgedPilot ProjectsAged, 80 and overNeoplasm StagingNeoplasm Invasiveness

Stichwörter der Autor:innen

Amino acid transportersKineticsMuscle-invasive bladder cancerStaging[18F]F-fluciclovine-PET/CT

Substanzen

Cyclobutanesfluciclovine F-18Carboxylic Acids

Autor:innen und Institutionen

  • Department of Imaging, Dana-Farber Cancer Institute, Boston, MA, USA. scng@mgb.org.
  • Joint Program in Nuclear Medicine, Harvard Medical School, Boston, MA, USA. scng@mgb.org.
  • Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA. scng@mgb.org.
  • Center for Systems Biology, Massachusetts General Hospital, Boston, MA, USA. scng@mgb.org.
  • Present/Permanent Address, 55 Fruit St, Boston, MA, 02115, USA. scng@mgb.org.
  • Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.

ORCID-Profile: Thomas S C Ng

Förderung

  • U.S. Department of Defense
  • NIH HHS
  • Lee Family Foundation
  • NIH

Zitieren

APA

Ng, T. S. C., Liu, M., Robertson, M., Könik, A., Cheng, S. C., Bakht, M. K., Harrington, K., Wolanski, A., Gilbert, L., Preston, M., Mossanen, M., Beltran, H., Hirsch, M. S., Sonpavde, G., & Jacene, H. A. (2025). A pilot study of [18F]F-fluciclovine positron emission tomography/computed tomography for staging muscle invasive bladder cancer preceding radical cystectomy. European Journal of Nuclear Medicine and Molecular Imaging, 52(11), 4092-4101. https://doi.org/10.1007/s00259-025-07287-y

Vancouver

Ng TSC, Liu M, Robertson M, Könik A, Cheng SC, Bakht MK, et al. A pilot study of [18F]F-fluciclovine positron emission tomography/computed tomography for staging muscle invasive bladder cancer preceding radical cystectomy. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(11):4092-4101. doi:10.1007/s00259-025-07287-y

BibTeX
@article{Ng2025,
  author = {Ng, Thomas S C and Liu, Mofei and Robertson, Matthew and Könik, Arda and Cheng, Su Chun and Bakht, Martin K and Harrington, Kristen and Wolanski, Andrew and Gilbert, Lauren and Preston, Mark and Mossanen, Matthew and Beltran, Himisha and Hirsch, Michelle S and Sonpavde, Guru and Jacene, Heather A},
  title = {A pilot study of [18F]F-fluciclovine positron emission tomography/computed tomography for staging muscle invasive bladder cancer preceding radical cystectomy},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {52},
  number = {11},
  pages = {4092--4101},
  doi = {10.1007/s00259-025-07287-y}
}
Kostenlos starten →